Regeneron Pharmaceuticals Inc

2026-09-09 19:36; UTC

Regeneron Pharmaceuticals is trading lower amid negative sentiment from a securities class action lawsuit regarding misleading statements about its Fianlimab-Libtayo Study.

2026-09-08 21:21; UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, reflecting positive momentum despite no specific news driving the movement.

2026-09-04 23:02; UTC

Regeneron Pharmaceuticals shares are trading higher in after-market hours, maintaining strength above its 20-day moving average and near the upper end of its one-month range.

2026-09-03 23:51; UTC

Regeneron Pharmaceuticals faces a class action lawsuit over misleading statements about its Phase III Fianlimab-Libtayo Study, with shares trading lower in after-market hours.

2026-09-02 20:01; UTC

Regeneron Pharmaceuticals gains as FDA approves Pasatru for fibrodysplasia ossificans progressiva, enhancing its rare disease portfolio amid ongoing Libtayo recall.

2026-09-01 20:01; UTC

Regeneron Pharmaceuticals is trading higher today, reflecting strong market activity, with the price above its 20-day moving average and near its one-month range.

2026-08-31 20:07; UTC

Regeneron Pharmaceuticals shares are higher, rebounding from earlier lows amid a broader market recovery and rising expectations for an interest rate hike.

2026-08-28 20:08; UTC

Regeneron Pharmaceuticals faces a securities fraud lawsuit over misleading statements, contributing to a market cap loss of $11 billion. Shares are lower since Thursday's close.

2026-08-27 23:01; UTC

Regeneron Pharmaceuticals shares are trading higher in after-market hours, recovering from an initial dip amid positive labor market data and no specific company news.

2026-08-26 23:11; UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours, reflecting a decline since Wednesday's close, with no specific news identified for the movement.

2026-08-25 19:26; UTC

Regeneron Pharmaceuticals selected Veeva Vault CRM for customer relationship management, enhancing operational efficiencies. Shares are modestly higher since Monday's close.

2026-08-24 23:36; UTC

Regeneron Pharmaceuticals shares are slightly higher in after-market hours, reaching a high of 1.09% above Monday's close. No specific news was identified for the move.

2026-08-21 23:46; UTC

Regeneron Pharmaceuticals Inc is trading lower in after-market hours, reflecting a slight decline since Friday's close, with no specific news identified.

2026-08-20 23:26; UTC

Regeneron Pharmaceuticals Inc shares are higher in after-market trading, maintaining a strong position above the 20-day moving average and near the one-month range.

2026-08-19 20:02; UTC

Regeneron Pharmaceuticals gained FDA approval for Pasatru, a treatment for a rare genetic disorder. Shares are advancing, reflecting strong investor sentiment.

2026-08-13 19:16; UTC

Regeneron Pharmaceuticals is trading higher as social media highlights REGN17235's potential in ongoing clinical trials, supporting strong performance since Wednesday's close.

2026-08-12 23:01; UTC

Regeneron Pharmaceuticals faces a securities fraud lawsuit over misleading statements regarding its Phase III Fianlimab-Libtayo Study, contributing to lower after-market trading.

2026-08-11 23:01; UTC

Regeneron Pharmaceuticals shares are modestly higher in after-market hours. No specific company news was identified to explain this movement.

2026-08-10 20:02; UTC

Regeneron Pharmaceuticals Inc shares are higher, supported by broader market strength and reduced expectations for Federal Reserve interest rate hikes following Friday's jobs report.

2026-08-07 22:16; UTC

Regeneron Pharmaceuticals shares are lower in after-market hours following a class action lawsuit alleging securities fraud and unlawful business practices.

2026-08-06 19:26; UTC

Regeneron Pharmaceuticals faces a potential class action lawsuit over alleged securities fraud, contributing to a decline in shares despite receiving Health Canada approval for Libtayo.

2026-08-05 20:06; UTC

Regeneron Pharmaceuticals is trading higher, reflecting gains since Tuesday, amid a decline in crude oil prices that eases inflationary pressures.

2026-08-04 23:46; UTC

Regeneron Pharmaceuticals is roughly flat in after-market trading, remaining well above its 20-day moving average and near the upper end of its one-month range.

2026-08-03 19:46; UTC

Regeneron Pharmaceuticals faces class action lawsuits over alleged securities fraud related to its Phase III Fianlimab-Libtayo Study, contributing to lower share prices.

2026-08-01 00:01; UTC

Regeneron Pharmaceuticals shares are lower in after-market hours following a class action lawsuit alleging securities fraud and concerns over a failed clinical trial.

2026-07-31 23:06; UTC

Regeneron Pharmaceuticals shares declined in after-market hours following a class action lawsuit alleging securities fraud related to its Phase III study modifications.

2026-07-30 19:49; UTC

Regeneron Pharmaceuticals is trading higher, significantly above its 20-day moving average and near the upper end of its one-month trading range.

2026-07-29 23:16; UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, maintaining strength above the 20-day moving average despite broader market caution over rising interest rates.

2026-07-28 23:06; UTC

Regeneron Pharmaceuticals Inc is higher in after-hours trading, continuing its positive momentum and remaining above its 20-day moving average. No specific news was identified.

2026-07-27 23:51; UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, maintaining momentum with strong cumulative returns and three consecutive higher daily closes.